Healthcare

EBR's prospects for its US heart lead improve as the wireless device...

EBR's prospects for its US heart lead improve as the wireless device receives approval for expedited reimbursement.

Optiscan (ASX:OIL) Initiates GI Study in Germany Using Its Initial I...

Optiscan Advances GI Imaging Technology with New Pre-Clinical Study

Is Little Green Pharma (ASX:LGP) Making Prudent Use of Debt?

Is Little Green Pharma (ASX:LGP) Making Prudent Use of Debt?

ASX Quarterly Health Summary: EZZ Scores Big, ReNerve's Initial Post...

EZZ Life Science and Microba Report Strong Q2 FY25 Growth

Lung Imaging Company Cyclopharm (ASX:CYC) Finds Success in the US Ma...

Cyclopharm's Strategic Expansion in the US Healthcare Market

How Will OPT-302 Transform the Future of Eye Disease Treatment?

Highlights,Opthea's lead drug, OPT-302, shows significant promise as a new treatment for challenging eye diseases, such as wet AMD and DME.,If Phase I...

Australian High-Growth Tech Stocks Highlighting Infomedia and Two Ad...

Australian High-Growth Tech Stocks Highlighting Infomedia and Two Additional Companies

Telix Pharmaceuticals (ASX:TLX) Gains After EU Approval for Illuccix...

Highlights,Telix,Pharmaceuticals (,ASX:TLX,) shares jump following European approval.,Illuccix,, the prostate cancer diagnostic agent, gets the green...

ResMed Gains Limelight as Goldman Sachs Sets Bullish Target

Highlights,Strong Performance:,ResMed shares have surged 44% in the past 12 months, showing robust investor confidence in the sleep disorder treatment...

Telix Pharmaceuticals Secures European Authorisation for Prostate Ca...

Highlights,European Approval for Illuccix®:,Telix Pharmaceuticals received a positive decision on its Marketing Authorization Application (MAA) for Il...

Immuron Reports Strong Sales Growth for Travelan® Across Global Mark...

Highlights,Global Sales Surge:,Travelan® global sales reached AUD $2.5 million in the December 2024 Quarter, up 70% from the prior quarter and 249% co...

Telix maintains steady growth, while Pro Medicus secures another con...

Telix maintains steady growth, while Pro Medicus secures another contract.

Will Recce Pharmaceuticals' R327G Gel Redefine Infection Treatment?

Highlights,Second phase trial completed with no serious adverse events reported,R327G gel developed for bacterial skin and skin structure infections,T...

How Is Singular Health Group Transforming Medical Imaging Efficiency...

Highlights:,Singular Health Group (ASX:SHG) completes Phase 1 of its MOU with Provider Network Solutions, showcasing technical proof of concept.,The c...

Phase III Trials: A Critical Moment for These ASX Health Stocks

Major ASX Biotechs Make Significant Advances in Phase III Trials

Dimerix Launches Key Paediatric Study in Groundbreaking Phase 3 Clin...

Highlights,Recruitment begins for the first paediatric patient in a pivotal kidney disease trial.,19 specialist sites across multiple countries involv...

Pro Medicus Signs $33M Deal with University of Kentucky

Highlights,Pro Medicus (ASX:PME) secures a long-term contract valued at $33 million.,Visage 7 Enterprise Imaging Platform to be implemented at Univers...

Pro Medicus (ASX:PME) Secures $33 Million Deal to Modernize Imaging...

Highlights,Pro Medicus (ASX:PME) signs a significant $33 million contract with the University of Kentucky.,Visage 7 cloud platform to replace outdated...

Chemist Warehouse Merger with Sigma Healthcare to Reshape the ASX 20...

Highlights,Sigma Healthcare (ASX:SIG) and Chemist Warehouse merger set to bring substantial index weight changes.,Analysts anticipate $537 million in...

Memphasys’ Antioxidant Profiling System Gains Recognition in Prestig...

Highlights:,Memphasys,Ltd (,ASX:MEM,) has received recognition for its proprietary,RoXsta,antioxidant profiling system through a key scientific public...